Equillium Inc

Equillium, Inc. engages in the development of products for severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. Its product pipeline includes EQ001, which is a monoclonal antibody that selectively targets the novel immune checkpoint receptor CD6. The company was founded by Daniel Mark Bradbury, Bruce D. Steel, and Stephen Connelly on March, 2017 and is headquartered in La Jolla, CA.

Earnings data Q3 2023

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that it will present at the Cantor Fitzgerald Global Healthcare Conference and the LD Micro Main Event Conference. Management will participate in a panel presentation at the Cantor Fitzgerald Conference where they will provide an overview of the Company's multi-cytokine inhibitor pl.

Equillium to Present at the Cantor Fitzgerald Global Healthcare & LD Micro Main Event Conferences

LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that it will host investor meetings at the Wells Fargo Healthcare Conference, and present and host meetings at the H.C. Wainwright 25th Annual Global Investor Conference. Management will provide an overview of the Company's multi-cytokine inhibi.

Equillium to Attend Wells Fargo Healthcare Conference & Present at H.C. Wainwright 25th Annual Global Investor Conference

Equillium, Inc. (EQ) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to loss of $0.41 per share a year ago.

Equillium, Inc. (EQ) Reports Q2 Loss, Tops Revenue Estimates

LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced financial results for the second quarter 2023 and provided corporate and clinical development updates. “We continue to advance our pipeline of wholly-owned and partnered clinical programs, and have deleveraged our ba.

Equillium Reports Second Quarter 2023 Financial Results and Provides Corporate and Clinical Updates

LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that its Board of Directors authorized the repurchase of up to $7.5 million of shares of the Company's common stock. “The share repurchase program demonstrates our belief in the intrinsic value and potential of Equillium and underscores our comm.

Equillium Announces $7.5 Million Share Repurchase Program

LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced that it will present at the Jefferies Global Healthcare Conference and the LD Micro Invitational Conference. Management will provide an overview of the Company's multi-cytokine inhibitor platform focused on EQ101 for the treatment of alopecia areata and.

Equillium to Present at the Jefferies Global Healthcare & LD Micro Invitational Conferences

LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ #celiacdisease--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced a poster was presented over the weekend at IMMUNOLOGY2023, the annual meeting of The American Association of Immunologists. The meetings are taking place at the Walter E. Washington Convention center in Washington, D.

Equillium Announces Poster Presentation at the Annual Meeting of The American Association of Immunologists

EQ sold option to purchase rights for Itolizumab to Ono Pharmaceutical: $26M upfront + program reimbursement + $37M if Ono exercises option right (~Q4 2024). Company now focused on 2 multi-cytokine inhibitor programs: alopecia areata (hair loss from immune reaction) and celiac disease.

Equillium: A Negative EV Biotech With Compelling Programs And Cash 'Til At Least 2025; Worth A Look

Equillium, Inc. (EQ) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.20. This compares to loss of $0.45 per share a year ago.

Equillium, Inc. (EQ) Reports Q1 Loss, Tops Revenue Estimates

LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced financial results for the first quarter 2023 and provided corporate and clinical development updates. “In the first quarter of 2023, we made excellent progress advancing Equillium's wholly-owned multi-cytokine inhibi.

Equillium Reports First Quarter 2023 Financial Results and Provides Clinical Updates

LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ #GVHD--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced that an ePoster presentation highlighting data from the EQUATE study in acute graft-versus-host disease (aGVHD) was given yesterday at the 49th Annual Meeting of the European Society for Blood and Marrow Transplantat.

Equillium Announces Poster Presentation at the Annual Meeting of the European Society for Blood and Marrow Transplantation

LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced financial results for the fourth quarter and full year 2022 and provided corporate and clinical development updates.

Equillium Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate & Clinical Development Updates

LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced that it will present at the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference.

Equillium to Present at the H.C. Wainwright Autoimmune & Inflammatory Disease Conference

LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ #GVHD--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that an oral presentation was given yesterday afternoon at the Tandem Meetings of the American Society of Transplantation and Cellular Therapy, and the Center for International Blood & Marrow Transplant Research. The oral presentation, given by Dr.

Equillium Announces Oral Presentation at the Tandem Meetings of ASTCT and CIBMTR

Equillium to Present at the SVB Securities Annual Global Healthcare Conference

LA JOLLA, Calif.--( BUSINESS WIRE )--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that an abstract was accepted for oral presentation at the Transplantation & Cellular Therapy Meetings of the American Society of Transplantation and Cellular Therapy, and the Center for International Blood & Marrow Transplant Research. The Hybrid meetings will take place virtually and in person at the Orlando World Center Marriott, Orlando, Florida, February 15 – 19, 2023.

Equillium Announces Abstract Accepted for Oral Presentation at the Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR

LA JOLLA, Calif.--( BUSINESS WIRE )--Equillium, Inc. (Nasdaq: EQ) and Metacrine, Inc. today announced the mutual termination of their previously announced definitive merger agreement.

Equillium and Metacrine Mutually Agree to Terminate Definitive Merger Agreement

LA JOLLA, Calif.--( BUSINESS WIRE )--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that Biocon Limited, in collaboration with Equillium, has initiated a Phase 2 clinical study of itolizumab in patients with ulcerative colitis (UC).

Equillium's Partner Biocon Initiates Phase 2 Study of Itolizumab in Ulcerative Colitis

LA JOLLA, Calif.--( BUSINESS WIRE )--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, and Ono Pharmaceutical Co., Ltd. (“Ono”), today announced an option and asset purchase agreement through which Ono gains the exclusive option to purchase Equillium's rights to itolizumab, a first-in-class monoclonal antibody targeting CD6. These rights include all therapeutic indications and the rights to commercialize itolizumab in the United States, Canada, Australia, and New Zealand.

Equillium and Ono Pharmaceutical Announce Exclusive Option and Asset Purchase Agreement for the Development and Commercialization of Itolizumab

Metacrine

NEW YORK,, Nov. 23, 2022 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Equillium, Inc. ("Equillium" or the "Company") (NASDAQ: EQ), in connection with its takeover of Metacrine, Inc. (Metacrine) (NASDAQ: MTCR). Under the terms of the merger agreement, Equillium will issue stock valued at a 25% premium over the Metacrine net cash delivered at closing, which is estimated to be approximately $26 million.

SHAREHOLDER ALERT: Weiss Law Investigates Equillium, Inc.

NEW YORK , Nov. 23, 2022 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Metacrine, Inc. ("Metacrine" or the "Company") (NASDAQ: MTCR), in connection with the acquisition of the Company by Equillium, Inc. ("Equillium") (NASDAQ: EQ). Under the terms of the merger agreement, Equillium will issue stock valued at a 25% premium over the net cash delivered at closing, which is estimated to be approximately $26 million.

SHAREHOLDER ALERT: Weiss Law Investigates Metacrine, Inc.

LA JOLLA, Calif.--( BUSINESS WIRE )--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced financial results for the third quarter 2022 and provided an update on its clinical development programs.

Equillium Reports Third Quarter 2022 Financial Results and Provides Corporate and Clinical Updates

LA JOLLA, Calif.--( BUSINESS WIRE )--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced that a poster presentation was given over the weekend at ACR Convergence, the annual meeting of the American College of Rheumatology. The presentation highlighted that levels of urinary soluble ALCAM (sALCAM) could be a potential biomarker of disease severity in lupus nephritis (LN) and indicative of a patient's response to treatment. The meeting, the world's premier rheumatology conference, is taking place November 10 – 14, 2022 at the Pennsylvania Convention Center in Philadelphia, Pennsylvania.

News for Equillium Inc Stock (EQ)